Summary
Cardinal Health Inc. (CAH) reported significant revenue growth of 9% to $86.9 billion in fiscal year 2007, driven primarily by its Pharmaceutical Supply Chain Services segment. However, operating earnings saw a substantial decline of 26% to $1.4 billion, largely impacted by $772 million in special items, including significant reserves for litigation settlements. The company also completed the divestiture of its PTS Business for $3.2 billion, using the proceeds for share repurchases and recording an $1.1 billion after-tax gain. Strategic acquisitions in respiratory care (Viasys) and infection management (MedMined) also bolstered its product offerings.
Key Highlights
- 1Revenue increased 9% year-over-year to $86.9 billion, primarily driven by the Pharmaceutical Supply Chain Services segment.
- 2Operating earnings decreased 26% to $1.4 billion, significantly impacted by $772 million in special items, notably litigation settlement reserves.
- 3The company completed the sale of its PTS Business for $3.2 billion, resulting in an after-tax gain of $1.1 billion.
- 4Strategic acquisitions of Viasys ($1.5 billion) and MedMined were completed, strengthening the Medical Products Manufacturing and Clinical Technologies and Services segments, respectively.
- 5The company repurchased approximately $3.8 billion of its common shares during fiscal 2007 under a $4.5 billion repurchase program.
- 6Cardinal Health faces significant customer concentration risk, with CVS and Walgreens accounting for approximately 40% of its revenue in fiscal 2007.
- 7The company is exposed to competitive pressures, healthcare industry changes, and regulatory scrutiny, including potential impacts from the Deficit Reduction Act of 2005.
Frequently Asked Questions
Revenue growth of 9% to $86.9 billion was primarily driven by the Healthcare Supply Chain Services -- Pharmaceutical segment, which saw a $6.5 billion increase. This growth was attributed to increased revenue from bulk customers ($4.0 billion), stemming from existing customers purchasing more volume and pharmaceutical price appreciation (6.3% index).
Operating earnings decreased by 26% to $1.4 billion due to $772 million in special items. The largest component of these special items was $655 million reserved for litigation settlements, including $600 million for the federal securities litigation and $40 million for ERISA litigation. In-process R&D expenses related to the Viasys acquisition also contributed.
Cardinal Health completed the sale of its PTS Business for approximately $3.2 billion in cash during the fourth quarter of fiscal 2007. The after-tax net proceeds of approximately $3.1 billion were used to repurchase the company's common shares.
Key risks include intense competitive pressures in its markets, substantial defaults or material reductions in purchases from large customers (like CVS and Walgreens, which accounted for 40% of revenue), and adverse changes in the U.S. healthcare environment (e.g., government funding, regulations, pricing pressures). The company also faces risks related to its acquisition strategy, potential disruptions from consolidating its headquarters, and managing product/component costs.